The Clostridium Difficile Infections market report provides an edge while developing business strategies, by understanding trends shaping and driving the global Clostridium Difficile Infections market. A detailed review of the historical and forecasted Clostridium Difficile Infections market is included in the report, covering drug outreach in the 7MM.
Clostridium Difficile Infections Overview
Clostridium difficile Infection (CDI), often called C. difficile or C. diff, is a gastrointestinal infection caused by bacterium Clostridium difficile. It commonly affects those individuals who have been exposed to antibiotics therapy, extended hospitalization, and long-term medical care.
Get Access to a Free Copy of Our Latest Sample Report @ https://www.delveinsight.com/sample-request/clostridium-difficile-infections-clostridium-difficile-associated-disease-market
Some of the key highlights of the Clostridium Difficile Infections Market Report
According to the 2017 annual report of Emerging Infections Program, in the US, the incidence of CDI was 48.53 and 77.49 cases per 100,000 in males and females, respectively in outpatient settings. The incidence at inpatient settings was 63 and 70.77 cases per 100,000 in males and females, respectively.
As per the article by Depestel et al. (2013), the data from North America and Europe suggest that approximately 20–27% of all CDI cases are community-associated, with an incidence of 20–30 per 100,000 population.
One of recent study published in Digestive Disease Week (DDW) 2021 Virtual Conference (2021), researchers observed that a decrease in hospital-acquired CDI infections in 2020 when compared to 2018 and 2019.
According to the Emerging Infections Program of Centers for Disease Control and Prevention, the male to female ratio of incidence is 0.75:1.
According to the literature review by Riley et al. (2018), the incidence rate of CDI in Japan were 0.8–4.71 per 10,000 patient-days and varied according to a setting, population, CDI definition, and detection method.
Clostridium Difficile Infections Epidemiology Insights
Clostridium Difficile Infections ranges from mild diarrhea to severe colon inflammation that can even be fatal. CDI usually occurs when people have taken antibiotics that change the normal colon bacteria and allowing the C. difficile bacteria to grow and produce its toxins.
Clostridium Difficile Infections Epidemiology Segmentation in the 7MM (2019-2032)
Total Clostridium Difficile Infections Incidence
Clostridium Difficile Infections Gender-specific Incident Cases
Clostridium Difficile Infections Age-specific Incident Cases
Clostridium Difficile Infections Incident Cases by recurrence
Clostridium Difficile Infections Treatable Cases
Clostridium Difficile Infections Market Insights
Vancocin (Vancomycin, ANI Pharmaceuticals) and Dificid (fidaxomicin, Optimer Pharmaceuticals) are the approved therapies for the treatment of CDI. Additionally, FDA has recently approved Firvanq (vancomycin, CutisPharma) for the treatment of Clostridium difficile associated diarrhea (CDAD). In October 2016, the US FDA approved bezlotoxumab (Zinplava) for use in the prevention of CDI recurrence in patient’s ≥18 years of age who are receiving treatment for CDI and are deemed at high risk for recurrent disease.
First step in the treatment of CDI involves stopping any antibiotics that may have triggered the C. difficile infection as soon as possible. The most commonly used therapies for C. diff are antibiotics. There are many types of antibiotics available, some of which move throughout the blood stream, and some that target certain areas of the body. The purpose of the treatment is to eradicate CDI and promote restoration of the normal colonic flora. Treatment of CDI depends on its severity.
Clostridium Difficile Infections Emerging Therapy Assessment
The dynamics of CDI market is anticipated to change in the coming years. Companies across the globe are working diligently toward the development of new treatment therapies for CDI.
Download Free Sample Report Now @ https://www.delveinsight.com/sample-request/clostridium-difficile-infections-clostridium-difficile-associated-disease-market
Table of content
1. Key Insights
2. Executive Summary of Clostridium Difficile Infections
3. Competitive Intelligence Analysis for Clostridium Difficile Infections
4. Clostridium Difficile Infections: Market Overview at a Glance
5. Clostridium Difficile Infections: Disease Background and Overview
6. Patient Journey
7. Clostridium Difficile Infections Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Clostridium Difficile Infections Unmet Needs
10. Key Endpoints of Clostridium Difficile Infections Treatment
11. Clostridium Difficile Infections Marketed Products
12. Clostridium Difficile Infections Emerging Therapies
13. Clostridium Difficile Infections: Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Market Outlook
16. Access and Reimbursement Overview of Clostridium Difficile Infections
17. KOL Views
18. Market Drivers
19. Market Barriers
21. DelveInsight Capabilities
23. About DelveInsight
Consult with our Business Expert @ https://www.delveinsight.com/sample-request/clostridium-difficile-infections-clostridium-difficile-associated-disease-market
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States